Trial Profile
The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in diabetic patients with coronary artery disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms IMAGINE-KOBE
- 25 Apr 2022 According to UMIN, Date of closure to data entry is 30 Mar 2019.
- 25 Apr 2022 Status changed from recruiting to completed.
- 05 Aug 2012 Actual initiation date added as reported by University Hospital Medical Information Network - Japan record.